BRAVECTO 250MG X 1TB (4.5-10KG)

Bravecto – external antiparasitic for dogs in the form of chewable tablets.

Indications:

For the treatment of tick and flea infestations in dogs.

This veterinary medicinal product is a systemic insecticide and acaricide that provides:

immediate and persistent killing activity for fleas (Ctenocephalides felis) for 12 weeks,
immediate and persistent tick killing activity for 12 weeks for Ixodes ricinus, Dermacentor reticulatus and D. variabilis
immediate and persistent tick killing activity for 8 weeks for Rhiphicephalus sanguineus.
Fleas and ticks must be attached to the host and feed in order to be exposed to the active substance. The onset of effect is 8 hours after attachment for fleas (C. felis) and 12 hours after attachment for ticks (I. ricinus).

The product can be used as part of the treatment strategy for the control of allergic dermatitis caused by fleas (DAP).

Each chewable tablet contains:

Bravecto chewable tablet Fluralaner (mg)

For very small dogs (2-4.5 kg) 112.5

For small dogs (>4.5-10 kg) 250

For medium-sized dogs (>10-20 kg) 500

For large dogs (>20-40 kg) 1,000

For very large dogs (>40-56 kg) 1,400

Tablets of different shades of brown with smooth or slightly rough surface and circular shape. Some marbling, spots, or both may be present.

Contraindications: Do not use in case of hypersensitivity to the active substance or to any of the excipients.

Adverse reactions:

Common adverse reactions observed in clinical trials (1.6% of treated dogs) were mild and transient gastrointestinal effects such as diarrhea, vomiting, inappetence and salivation.

The frequency of adverse reactions is defined using the following convention:

– very common (more than 1 in 10 animals showing adverse reactions during a treatment)

– common (more than 1 but less than 10 in 100 animals)

– uncommon (more than 1 but less than 10 animals in 1,000 animals)

– rare (more than 1 but less than 10 animals in 10,000 animals)

– very rare (less than 1 animal in 10,000 animals, including isolated reports)

If you notice serious reactions or other effects not mentioned in this leaflet, please inform your veterinarian.

Target species: Dogs.

Models:

Bravecto 112.5 mg chewable tablets for very small dogs (2-4.5 kg)
Bravecto 250 mg chewable tablets for small dogs (>4.5-10 kg)
Bravecto 500 mg chewable tablets for medium-sized dogs (>10-20 kg)
Bravecto 1000 mg chewable tablets for large dogs (>20-40 kg)
Bravecto 1400 mg chewable tablets for very large dogs (>40-56 kg) Fluralaner

Dosage for each species, route of administration and mode of administration

For oral administration.

Bravecto should be administered in accordance with the following table (corresponding to the dose of 25.56 fluralaner/kg body weight corresponding to the body weight band):

Body weight of the dog (kg) Concentration and number of tablets to be administered
Bravecto 112.5 mg Bravecto 250 mg Bravecto 500 mg Bravecto 1000 mg Bravecto 1400 mg
2-4.5 1                
>4.5-10 1            
>10-20 1        
>20-40 1    
>40-56 1
Recommendations for proper administration

For dogs over 56 kg body weight, use a combination of two tablets that best matches the animal's weight.
Chewable tablets should not be broken or split.
Bravecto chewable tablets are taken at or around feeding time.
Bravecto is a chewable tablet and is well tolerated by most dogs. If the tablet is not taken voluntarily by the dog, it can also be administered with food or directly in the oral cavity.
The dog should be observed during administration to confirm that the tablet is swallowed.